Pfizer Faces 1st Damages Trial In 2021 Over Axed Lyrica IP

Law360, London (December 18, 2020, 7:06 PM GMT) -- A judge ordered a preliminary issues trial as soon as June for claims totaling hundreds of millions of pounds against Pfizer from the NHS and generic drug companies due to an injunction blocking rivals to its blockbuster anti-convulsant Lyrica over a patent ultimately invalidated by the U.K. Supreme Court.

High Court Judge Colin Birss told the parties Friday to arrange the dates with the court's listing office and to set aside four trial days "well before the end of 2021."

The claims for damages from the NHS and generic-drug giants such as Actavis and Sandoz arise from a long-running dispute over...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!